Table 3 Reduced intensity regimens
Conditioning regimen | Drug | Dose (total) | Schedule(d) | Donor type |
|---|---|---|---|---|
Flu/Mel | Flu | 150 mg/m2 | − 7 to  − 3 | Allo-HSCT |
Mel | 140 mg/m2 | − 2, − 1 | ||
Flu/Bu | Flu | 150 mg/m2 | − 9 to  − 5 | Allo-HSCT |
Bu | 8–10 mg/kg (po) | − 6 to  − 4 | ||
Flu/Cy | Flu | 150 mg/m2 | − 7 to  − 3 | Allo-HSCT |
Cy | 140 mg/m2 | − 2, − 1 | ||
Flu/Bu/TT | Flu | 150 mg/m2 | − 7 to  − 5 | Allo-HSCT |
Bu | 8 mg/kg (po) | − 6 to  − 4 | ||
Thiotepa | 5 mg/kg | − 3 | ||
RIC-BuFlu  ± ATG | Ara-C | 2–4 g/m2 | − 9 | MSD-HSCT |
Bu | 9.6 mg/kg (iv) | − 8 to  − 6 | ||
Flu | 150 mg/m2 | − 6 to  − 2 | ||
MeCCNU | 250 mg/m2 | − 3 | ||
ATG * | 4.5 mg | − 4 to − 2 | ||
RIC-mBuCyFlu + ATG | Ara-C | 4–8 g/m2 | − 10, − 9 | URD,CB,HID-HSCT |
Bu | 9.6 mg/kg (iv) | − 8 to  − 6 | ||
Flu | 150 mg/m2 | − 6 to  − 2 | ||
Cy | 2.0 g/m2 | − 5, − 4 | ||
MeCCNU | 250 mg/m2 | − 3 | ||
ATG | 7.5–10 mg/kg | − 5 to  − 2 |